NKTX - Nkarta, Inc.
After hours:
Chart Events
Momentum
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 4.5000 |
| Open | 4.5500 |
| Bid | 4.3400 x 800 |
| Ask | 4.6500 x 800 |
| Day's Range | 4.4800 - 4.5900 |
| 52 Week Range | 3.1200 - 18.4800 |
| Volume | |
| Avg. Volume | 388,811 |
| Market Cap | 222.654M |
| Beta (5Y Monthly) | 0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4500 |
| Earnings Date | Aug 09, 2023 - Aug 14, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.25 |
Fair Value
Related Research
GlobeNewswireNkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023Cash and cash equivalents of $332.1 million on March 31, 2023Cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter ended March 31, 2
- GlobeNewswire
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will present preliminary data from its Phase 1 dose escalation clinical trial of NKX019 at two upcoming scientific conferences in June 2023: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML). NKX019 is an allogeneic,
Simply Wall St.We're Hopeful That Nkarta (NASDAQ:NKTX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
InvestorPlace7 Stocks With Promising Upside Potential for 100% Returns
While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you’re just in the mood for stocks with 100% upside potential. And with these ideas, you’re going to get that and more, assuming the stars align correctly. Of course, that’s a major assumption. All of the best stocks to double your money here may do so within a 12-month period. It’s just that you should also prepare for the real possibility of significant losses. Basically, in exchang
- GlobeNewswire
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
Improved ADCC with ADAM17 gene knockout of NK or CAR NK cells, supporting ADAM17 KO use for clinical applications Increased specific killing of cancer cells in vitro by the combination of NKX101 and cetuximab, supporting use for combination in solid tumors SOUTH SAN FRANCISCO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of two preclini
- GlobeNewswire
Nkarta to Participate at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences: 22nd Annual Needham Virtual Healthcare ConferenceApril 17, 20233:00 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 20, 20233:00 p.m. ET – panel discussion A simultaneous webcast of each event w
InvestorPlace3 Biotech Stocks to Watch for Potential Breakthroughs
Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs. Those costs are subsidized on the back end upon commercial success, often leading to extremely high sales. Investing in biotech stocks is often about identifying the next potential breakthrough therapeutics and devices. That likely, even at the earliest stages of the development process
- GlobeNewswire
Nkarta Announces Departure of Chief Financial & Business Officer
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that Nadir Mahmood, PhD, has resigned his position as chief financial and business officer to serve as the chief executive officer of a private biotechnology company. Dr. Mahmood will re
- GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 20232022 year-end cash and cash equivalents of $354.9 millionCash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Cl
- Simply Wall St.
Nkarta, Inc. (NASDAQ:NKTX) is a favorite amongst institutional investors who own 58%
To get a sense of who is truly in control of Nkarta, Inc. ( NASDAQ:NKTX ), it is important to understand the ownership...
- GlobeNewswire
Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotion of David R. Shook, M.D., to the role of Chief Medical Officer. Dr. Shook has extensive expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. “Dave has been a driving force behind the developm
- GlobeNewswire
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cyclesPatients with CR observed across multiple NHL histologies, including LBCLConsolidation dosing administered to 7 patients with CRs with aim to eradicate residual tumor cells and prolong responseDurable res
- GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019 NK Cell Therapy Program
Call scheduled for Monday, December 5, 2022 at 8:00 a.m. ETSOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate. Conference Call and Webcast
- GlobeNewswire
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
NKX101 and NKX019 allogeneic cell therapy programs continue to advance following initial clinical data reported in April 2022NKX019 Phase 1 clinical trial recently opened dose expansion cohortsNKX019 clinical update is expected by year-end 2022NKX101 clinical update is expected in first half of 2023Presentations at SITC 2022 on enhanced anti-tumor activity of NKX019 when combined with CD20-targeted monoclonal antibodies in preclinical models, and next-generation commercial-scale NK cell manufact
- GlobeNewswire
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
Improved Anti-Tumor Activity Demonstrated by the Combination of NKX019 and a CD20-directed Monoclonal Antibody in Preclinical Models Pulsed Stimulation of NK Cells Derived from Peripheral Blood of Healthy Donors Induces Billion-Fold Expansion, Enabling Commercial-Scale Production of NK Cell Therapy from a Selected Single Donor SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell ther
- Simply Wall St.
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- InvestorPlace
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time. Similarly, biotech stocks can skyrocket on the commercialization of potential blockbuster drugs. With the covid-19 pandemic, investments have surged in the biotechnology sector. As the research pipeline for various conditions deepens, the investment opportunities continue to expand. My view is underscored
- GlobeNewswire
Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights
Positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL validate the company’s platform for engineered CAR NK cell therapy candidatesAdditional NKX101 and NKX019 clinical data expected by year-end 2022; data expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses S
ZacksShould You Buy Nkarta (NKTX) Ahead of Earnings?
Nkarta (NKTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
TipRanksOver 100% Upside: Analysts See an Appealing Entry Point in These 3 ‘Strong Buy’ Stocks
After July’s exceptional surge, the markets steadied during early August with the S&P 500 up by a third of a precent over the past week. Now investors will be keen to find out if the rally has legs. Stifel's chief equity strategist Barry Bannister thinks it does and believes the S&P 500 is on course to reach 4,400 during the year’s second half, explaining that the sell-off in 1H22 is “still being reversed.” The strategist also thinks the S&P 500’s “equity risk premium” now suggests a mid-point p
- GlobeNewswire
Nkarta Announces Key Senior Leadership Team Appointments
Ralph Brandenberger, PhD, promoted to Chief Technical OfficerYvonne Li, MBA, promoted to Chief Administrative OfficerEvolution of Nkarta leadership team to support rapid development of allogeneic, off-the-shelf NK cell therapies SOUTH SAN FRANCISCO, Calif. , July 25, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the promotions of Ralph Brandenberger, PhD, t
BenzingaSVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
SVB Leerink initiated coverage on Nkarta Inc (NASDAQ: NKTX) with an Outperform rating and a price target of $30 (117% implied upside). The analysts believe Nkarta is well-positioned to compete given the company's deep biologic expertise in NK cells, as evidenced by extensive publication on programs and fundamental biology. Nkarta's donor peripheral blood-derived NK cell platform is a commercially scalable platform with validated component technologies, SVB writes. Related: Investors Cheer Nkarta
- Simply Wall St.
What Is The Ownership Structure Like For Nkarta, Inc. (NASDAQ:NKTX)?
A look at the shareholders of Nkarta, Inc. ( NASDAQ:NKTX ) can tell us which group is most powerful. Large companies...
ZacksWall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know
The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- GlobeNewswire
Nkarta to Participate at Upcoming Investor Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference: Cowen 3rd Annual Oncology Innovation SummitJune 2, 202211:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on t